Matinas BioPharma Investor Presentation Deck

9 EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity collo Exceeded the primary endpoint threshold EFA for MAT2203 was 0.42 (95% CI 0.29 to 0.55) (primary endpoint threshold was 0.20) 6 All patients completing induction achieved CSF sterility 97% for patients receiving MAT2203 76% for patients receiving SOC Mi No breakthrough Infections Over 10 weeks, patients showed no breakthrough infections post-MAT2203 treatment COPYRIGHT MATINAS BIOPHARMA ● + Survival at Day 30 98% for patients receiving MAT2203 2024 88% for patients receiving IV AMPB (SOC) Ⓡ MAT2203 was safe and well-tolerated over 6 weeks of treatment Repeat dosing showed no renal toxicity or electrolyte abnormalities No discontinuations due to AEs nor MAT2203-related SAEs MATINAS BIOPHARMA

View entire presentation